New combination therapy shows promise in metastatic pancreatic cancer
Results from an early-stage clinical trial, published in Nature Communications, showed encouraging outcomes among patients with newly diagnosed cancer whose tumors had spread to distant organs. Most strikingly, one patient experienced a pathologic complete response—meaning no viable cancer cells could be found—and remains cancer-free for more than two years without further treatment. These…
An early-stage clinical trial, published in Nature Communications, has shown promising results for a new combination therapy targeting metastatic pancreatic cancer. The treatment, which combines CXCR4 inhibition, immune checkpoint inhibition, and chemotherapy, was tested on 11 patients with newly diagnosed cancer whose tumors had spread to distant organs.
Remarkably, one patient experienced a pathologic complete response, meaning no viable cancer cells were found and remained cancer-free for more than two years without further treatment. This is a rare and significant outcome in metastatic pancreatic cancer. The lead investigator, Dr. Gulam Manji, emphasized the importance of developing new tools to overcome pancreatic cancer's resistance to immunotherapy, which has been less effective compared to other cancers.
Pancreatic cancer's tumor microenvironment, which includes immune cells, connective tissue, blood vessels, and other components, is particularly immunosuppressive, shielding the tumor from immune attack. The combination therapy targets this environment from multiple angles, potentially breaking through the cancer's defenses. However, the therapy may also trigger the development of new defenses as the cancer adapts.
The trial revealed that treatment order mattered, with blocking CXCR4 first creating an opening for the subsequent therapies. Researchers used advanced single-cell and computational technologies to map how individual cancer and immune cells changed in response to treatment, providing insights into the mechanisms of action and potential resistance. Future clinical trials and laboratory studies will focus on identifying biomarkers that predict patient response and understanding tumor evolution as resistance develops.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
